Market research
INMB INmune Bio Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 64M
- P/E ratio
- Not available
- Analyst target
- 7
- Beta
- Not available
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US45782T1051
- Market cap
- 64M
- P/E ratio
- Not available
- Analyst target
- 7
- Beta
- Not available
About
About INmune Bio Inc
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; GOSH; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the INMB discussion.
5 years, 4 months ago
INmune Bio, Inc is currently in a long term uptrend where the price is trading 30.3% above its 200 day moving average.
From a valuation standpoint, the stock is 910.2% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 13530.4.
INmune Bio, Inc's total revenue rose by inf% to $11K since the same quarter in the previous year.
Its net income has dropped by 38.2% to $-3M since the same quarter in the previous year.
Finally, its free cash flow fell by 452.1% to $-2M since the same quarter in the previous year.
Based on the above factors, INmune Bio, Inc gets an overall score of 2/5.